Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Molecular Partners AG ADR(MOLN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MOLN
09/25/2026: MOLN (1-star) is currently NOT-A-BUY. Pass it for now.
Molecular Partners AG is a clinical-stage biotechnology company focused on developing its proprietary DARPin protein platform for oncology. Its primary strength lies in the modularity and specificity of its technology, which has attracted significant partnerships with major pharmaceutical players. The investment story centers on the success of its oncology pipeline, specifically candidates designed to activate immune responses. Key risks include the binary nature of clinical trials, substantial cash requirements, and competition from more established antibody-based therapies. The stock is best suited for risk-tolerant investors looking for long-term growth through technological disruption, and investors should closely monitor clinical trial milestones and future collaboration updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward play suitable only for investors willing to bet on the success of a niche technology platform. |
| Momentum investor | Weak fit | The stock often lacks sustained upward momentum unless catalyzed by specific clinical trial data releases. |
| Value investor | Weak fit | Valuation is difficult due to the lack of steady earnings and the early-stage nature of the product pipeline. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on research and development. |
| Low-risk investor | Weak fit | The stock carries high volatility inherent to clinical-stage biotech investments. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is extremely sensitive to clinical trial outcomes and biotech sector news. |
| Valuation risk | High | Valuations for pre-revenue biotech companies are speculative and subject to rapid correction. |
| Competition risk (antibody developers) | Medium / high | Established antibody therapies have a significant head start in market penetration and clinician familiarity. |
| Business quality | Medium | While the technology is innovative, the company lacks a diversified commercial portfolio. |
| Dividend income | Low / none | There is no income generation for investors through dividends. |
| Execution risk | High | Failure at any stage of clinical trials could result in a significant loss of value for investors. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 27.85% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 164.71M USD | Price to earnings Ratio - | 1Y Target Price 10.43 |
Price to earnings Ratio - | 1Y Target Price 10.43 | ||
Volume (30-day avg) 1.4K shares | Beta 0.69 | 52 Weeks Range 3.53 - 5.36 | Updated Date 09/25/2026 |
52 Weeks Range 3.53 - 5.36 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research Collaborations | Milestone payments and R&D funding from pharmaceutical partners. | The company generates cash primarily by partnering its technology with larger, established drug companies. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1.7 | Enterprise Value 77.74M | Price to Sales(TTM) 156.56 |
Enterprise Value 77.74M | Price to Sales(TTM) 156.56 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA 1.23 | Shares Outstanding 38.31M | Shares Floating 20.71M |
Shares Outstanding 38.31M | Shares Floating 20.71M | ||
Percent Insiders - | Percent Institutions 9.38 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Molecular Partners AG ADR
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2021-06-16 | Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | |
Full time employees 134 | |||
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.